Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Public ClinicalTrials.gov record NCT02797470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells
Study identification
- NCT ID
- NCT02797470
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- HIV Infection
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Plasmablastic Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Non-Hodgkin Lymphoma
- Recurrent Burkitt Lymphoma
- Recurrent Follicular Lymphoma
- Stage III Follicular Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Follicular Lymphoma
- Stage IV Mantle Cell Lymphoma
Interventions
- Autologous Hematopoietic Stem Cell Transplantation Procedure
- Carmustine Drug
- Cytarabine Drug
- Etoposide Drug
- Laboratory Biomarker Analysis Other
- Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells Biological
- Melphalan Drug
- Peripheral Blood Stem Cell Transplantation Procedure
Procedure · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 22, 2016
- Primary completion
- May 12, 2021
- Completion
- Feb 29, 2036
- Last update posted
- Apr 19, 2025
2016 – 2036
United States locations
- U.S. sites
- 4
- U.S. states
- 2
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| UCSF Medical Center-Parnassus | San Francisco | California | 94115 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02797470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02797470 live on ClinicalTrials.gov.